ArticleTranslational lung cancer research2023
Identification of lysosomal genes associated with prognosis in lung adenocarcinoma.
Article in Translational lung cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Characterization of natural killer (NK) cells in lung adenocarcinoma and construction of an NK risk signature based on single-cell and macromolecular RNA-seg data.Discover oncology · 2026Article
- Integrated analysis of scRNA-seq and bulk RNA-seq identifies matrisome-related biomarkers for prognostic stratification and immune landscape in lung adenocarcinoma.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026Article
- Prognostic value and biological role of STING-related genes GAB3 and IL16 in lung adenocarcinoma: implications for immune evasion and treatment.Scientific reports · 2025Article
- The role of immunogenic cell death in the prognosis and development of treatment strategies for non-small cell lung cancer: a multiomics and machine learning approach for predictive and personalized treatment.Translational lung cancer research · 2025Article
- CoxKAN: Kolmogorov-Arnold networks for interpretable, high-performance survival analysis.Bioinformatics (Oxford, England) · 2025Article
- Article
- TFAP2A upregulates FAM83A to suppress ferroptosis and diminish cisplatin sensitivity in non-small cell lung cancer.Cell division · 2025Article
- Zinc Finger Protein-Based Prognostic Signature Predicts Survival in Lung Adenocarcinoma.Cancers · 2025Article
- Prognostic significance ofTranslational cancer research · 2025Article
- Development of a reliable risk prognostic model for lung adenocarcinoma based on the genes related to endotheliocyte senescence.Scientific reports · 2025Article
- Article
- Role of Radiation-related Lung Function Genes in Prognosis and Immune Infiltration of Lung Adenocarcinoma.Combinatorial chemistry & high throughput screening · 2025Article
- Construction of AML prognostic model with CYP2E1 and GALNT12 biomarkers based on golgi- associated genes.Annals of hematology · 2024Article
- Integrative analysis of pan-cancer single-cell data reveals a tumor ecosystem subtype predicting immunotherapy response.NPJ precision oncology · 2024Article
- Article
- Identification of a novel ADCC-related gene signature for predicting the prognosis and therapy response in lung adenocarcinoma.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Article
- Article
- LINC01559 promotes lung adenocarcinoma metastasis by disrupting the ubiquitination of vimentin.Biomarker research · 2024Article
- Development and validation of a DNA damage repair-related gene-based prediction model for the prognosis of lung adenocarcinoma.Journal of thoracic disease · 2023Article
- Establishment of a lysosome-related prognostic signature in breast cancer to predict immune infiltration and therapy response.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer, representing 40% of all cases of this tumor. Despite immense improvements in understanding the molecular basis, diagnosis, and treatment of LUAD, its recurrence rate is still high. Methods: RNA-seq data from The Cancer Genome Atlas (TCGA) LUAD cohort were download from Genomic Data Commons Portal. The GSE13213 dataset from Gene Expression Omnibus (GEO) was used for external validation. Differential prognostic lysosome-related genes (LRGs) were identified by overlapping survival-related genes obtained via univariate Cox regression analysis with differentially expressed genes (DEGs). The prognostic model was built using Kaplan-Meier curves and least absolute shrinkage and selection operator (LASSO) analyses. In addition, univariate and multivariate Cox analyses were employed to identify independent prognostic factors. The responses of patients to immune checkpoint inhibitors (ICIs) were further predicted. The pRRophetic package and rank-sum test were used to compute the half maximal inhibitory concentrations (IC Results: Of the nine candidate differential prognostic LRGs, Conclusions: Four key prognostic biomarkers-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.